Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system.

In an era of continuous advancements in medical technology, Edwards Lifesciences (NYSE: EW), a global leader in ...

The transcatheter mitral valve replacement (TMVR) market is projected to grow at a CAGR of 20% over the forecast ...

Breakthroughs in tricuspid and mitral valve repair signal progress in heart treatment. BEIJING, June 3, 2025 /PRNewswire/ -- ...

The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology ...

US FDA approves Abbott’s Tendyne, first-of-its-kind device to replace the mitral valve without open-heart surgery: Abbott Park, Illinois Thursday, May 29, 2025, 16:00 Hrs [IST] ...

Among patients with atrial functional mitral regurgitation, severe tricuspid regurgitation is common and associated with worse outcomes.

The US Food and Drug Administration has approved Abbott's Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. It is indicated for patients with mitral valve disease caused by ...

A patient who was one of a region's first to have a new heart procedure says it helped her get her life back. Valerie Wells, ...

In July 2024, a team of surgeons at NewYork-Presbyterian Children’s Hospital of New York—Morgan Stanley Children’s Hospital performed a split-root domino partial heart transplant, saving the life of ...

According to a medical report from the Edward Francis Small Teaching Hospital (EFSTH), Musa has been diagnosed with Rheumatic ...